Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Trial Details
- NCT ID
- NCT06616597
- Phase
- PHASE2
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- Abiraterone acetate
- Dexamethasone
- Metronidazole
- Locations (sample)
- Baltimore, Maryland, United States|39.29038,-76.61219
Key Eligibility Criteria
- Males aged 18 years of age and above.
- Prostate adenocarcinoma
- Absolute PSA ≥ 2.0 ng/mL at screening.
- PSA (+/- radiographic) progression after having been on abiraterone and prednisone for at least 12 weeks.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →